MADRIGAL PHARMACEUTICALS INC financial statements, including revenue, expenses, profit, and loss
The total revenue of YDO1 for the last quarter is 55.84 M EUR, and it's 308.62% higher compared to the previous quarter. The net income of Q3 24 is -96.07 M EUR.